trending Market Intelligence /marketintelligence/en/news-insights/trending/aE1pi854Evc8y7V6YmpM3Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca-Merck's Lynparza gets US FDA priority review in ovarian cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca-Merck's Lynparza gets US FDA priority review in ovarian cancer

AstraZeneca PLC and Merck & Co. Inc.'s Lynparza was granted priority review in the U.S. as initial maintenance therapy for patients with advanced ovarian cancer.

The U.S. Food and Drug Administration is expected to make a decision on the companies' medicine in the second quarter of the year. If approved, Lynparza, or olaparib, will be available for patients with advanced ovarian cancer who are in complete or partial response to initial treatment with Roche Holding AG's Avastin, or bevacizumab.

As a maintenance treatment, Lynparza would be expected to bolster the effects of Avastin. Data from a phase 3 trial called Paola-1 has already demonstrated that using Lynparza as a maintenance treatment helps extend the lives of patients who have received Roche's drug.

Lynparza is already approved across multiple cancer indications around the world, including in parts of Asia, as well as in the EU. In the U.S., Lynparza is approved as maintenance therapy for women with certain types of ovarian, fallopian tube and peritoneal cancer who benefit from chemotherapy.